Antares Pharma, Inc. Release: Subcutaneous, Self-Administered Methotrexate for Rheumatoid Arthritis Demonstrated Significantly Greater Bioavailability Over Current Standard of Care
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced subcutaneous methotrexate delivered with a new, self-administration device demonstrates bioavailability that is significantly greater than oral methotrexate in the treatment of adults with rheumatoid arthritis. The clinical study results were presented at the 2013 European League Against Rheumatism (EULAR) Annual Congress. The data are from a randomized, open-label, three-way crossover study that found four hours after dose, blood concentrations of subcutaneously, self-administered methotrexate were consistently higher than concentrations of orally dosed methotrexate at all levels studied.
Help employers find you! Check out all the jobs and post your resume.
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced subcutaneous methotrexate delivered with a new, self-administration device demonstrates bioavailability that is significantly greater than oral methotrexate in the treatment of adults with rheumatoid arthritis. The clinical study results were presented at the 2013 European League Against Rheumatism (EULAR) Annual Congress. The data are from a randomized, open-label, three-way crossover study that found four hours after dose, blood concentrations of subcutaneously, self-administered methotrexate were consistently higher than concentrations of orally dosed methotrexate at all levels studied.
Help employers find you! Check out all the jobs and post your resume.